Lasting tumor regression of leukemia and lymphoma in mouse models achieved by U-M compound

(Michigan Medicine - University of Michigan) For decades, a transcription factor known as STAT3 has been a major therapeutic target in the treatment of cancer, but it has largely been considered 'undruggable' due to the difficulty of developing compounds to effectively inhibit its activity. Researchers at the University of Michigan Rogel Cancer Center have taken a promising new approach to targeting STAT3 -- one that was able to achieve a long-lasting and nearly complete elimination of tumors in mouse models of leukemia and lymphoma, the authors report in Cancer Cell.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

Most patients with diffuse large B-cell lymphoma who have a clear PET scan...Read more on AuntMinnie.comRelated Reading: Cancer patients want more info on treatment downside CT radiation increases risk of thyroid cancer, leukemia ASTRO: Radiation can nix side effects of T-cell therapy ASTRO: AI predicts side effects from radiation therapy Routine PET field-of-view enough for pediatric lymphoma
Source: Headlines - Category: Radiology Source Type: news
AbstractAccess to reliable, up-to-date information and resources can assist individuals managing and living with cancer. The Leukemia&Lymphoma Society, through its Information Resource Center, provides personalized information and support to individuals affected by blood cancer. To examine its value and impact, we conducted qualitative interviews (n = 18) and an online survey of patients and caregivers (N = 515) after they talked with an Information Resource Center Information Specialist by phone, with a follow-up survey about 6 months later. Respondents most commonly contacted the Information Resource Center to get re...
Source: Journal of Cancer Education - Category: Cancer & Oncology Source Type: research
We present a contemporary analysis of risk of fatal stroke among more than 7.5 million cancer patients and report that stroke risk varies as a function of disease site, age, gender, marital status, and time after diagnosis. The risk of stroke among cancer patients is two times that of the general population and rises with longer follow-up time. The relative risk of fatal stroke, versus the general population, is highest in those with cancers of the brain and gastrointestinal tract. The plurality of strokes occurs in patients older than 40 years of age with cancers of the prostate, breast, and colorectum. Patients of any ag...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Biphenotypic Acute Leukemia;   Undifferentiated Leukemia;   Prolymphocytic Leukemia;   Myelodysplastic Syndromes;   Chronic Myelogenous Leukemia;   Myeloproliferative Neoplasm;   Relapsed Large Cell Lymphoma;   Man tle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Smal...
Source: - Category: Research Source Type: clinical trials
Conclusions: CD200 has a great impact in diagnosing B- chronic lymphoproliferative disorders, especially when we want to determine the origin of a CD19, CD5 positive population and distinguish between CLL and MCL. CD 23 is a reliable marker in those cases, but, as we showed, CD23 might have a lower specificity than CD200 for CLL. We added CD200 in our panels in order to diagnose chronic lymphoproliferative disorders, not to replace CD 23, but to improve and save time in our diagnostic process. The high expression of CD200 in CLL and HCL could open the option for new- targeted therapy (anti-CD200). PMID: 31803290 [PubMed]
Source: Journal of Medicine and Life - Category: General Medicine Tags: J Med Life Source Type: research
Conditions:   Leukemia;   Lymphoma;   Blood Cancer;   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia;   Non-Hodgkins Lymphoma Intervention:   Other: Bone Marrow Transplant (BMT) Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Institutes of Health (NIH);   National Institute on Aging (NIA) Recruiting
Source: - Category: Research Source Type: clinical trials
(University of Texas Health Science Center at San Antonio) A new class of drugs degrades an essential survival protein in cancer cells while sparing platelets. Therefore, it could be a safer therapy for multiple types of leukemia and lymphoma, say researchers at UT Health San Antonio.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Publication date: 3 December 2019Source: Cell Reports, Volume 29, Issue 10Author(s): Hamidullah Khan, Ashish Anshu, Aman Prasad, Sushmita Roy, Justin Jeffery, Wasakorn Kittipongdaja, David T. Yang, Stefan M. SchiekeSummaryMetabolic flexibility allows cells to adapt to various environments and limits the efficacy of metabolic drugs. Therapeutic targeting of cancer metabolism relies on defining limiting requirements and vulnerabilities in the highly dynamic metabolic network. Here, we characterize the metabolic reprogramming and identify cancer-specific metabolic vulnerabilities in response to the pharmacological inhibition ...
Source: Cell Reports - Category: Cytology Source Type: research
Abstract LSP1 (Lymphocyte-specific protein 1) protein plays an important role in neutrophil motility, fibrinogen matrix proteins adhesion, and trans-endothelial migration. Variation in the LSP1 gene is associated with leukemia and lymphomas in tumor cells of Hodgkin's disease and breast cancer. Despite extensive study on the human LSP1, a comprehensive analysis on the Single Nucleotide Polymorphism (SNPs) of the gene is not available. Therefore, it is of interest to identify, collect, store and analyze the SNPs of the LSP1 gene in relation to several known diseases. Hence, the SNP data (398 rsids) from dbSNP datab...
Source: Bioinformation - Category: Bioinformatics Authors: Tags: Bioinformation Source Type: research
More News: Cancer | Cancer & Oncology | Leukemia | Lymphoma